



Targeted Radionuclide Tumor Therapy

Guest Editors:

Prof. Dr. Vladimir Tolmachev

Department of Immunology,
Genetics and Pathology (IGP),
Dag Hammarskjölds väg 20
Uppsala University, SE-751 85
Uppsala, Sweden

Dr. Mohamed Altai

Division of Oncology and
Pathology, Department of
Clinical Sciences, Kamprad
Laboratory, Lund University,
22243 Lund, Sweden

Deadline for manuscript
submissions:

closed (30 September 2019)

Message from the Guest Editors

In the era of personalized cancer treatment there has been a great emphasis on targeted therapy. Targeted radionuclide therapy represents a promising therapeutic strategy for the treatment of patients with disseminated cancer. The success of targeted radionuclide therapy in malignant lymphomas has proven that this approach is feasible, effective and clinically translatable. However, the full translation of this approach to solid tumours was restricted by low tumour accumulation, normal tissue toxicity and an intrinsically greater radioresistance. There has recently been progress in the treatment of solid tumours with targeted radionuclide therapy, particularly in patients with somatostatin receptor-positive neuroendocrine tumours. This has opened the door to the development of new radionuclide-based targeting agents with therapeutic potential. As stated, the development of new targeted radionuclide therapies and their translation into clinical practice represents a great challenge in the field. This Special Issue has the aim of highlighting current progress in the development of potential targeting agents for targeted radionuclide therapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma